Literature DB >> 16716414

Antiviral therapy of chronic hepatitis B.

Fabien Zoulim1.   

Abstract

Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a major goal of antiviral therapy to improve the clinical outcome of the patients. Antiviral treatment of chronic hepatitis B relies currently on immune modulators such as interferon alpha and its pegylated form, and viral polymerase inhibitors. Because of the slow kinetics of viral clearance and the spontaneous viral genome variability, viral mutants resistant to nucleoside analogs may be selected. However, the development of new antiviral agents is rapidly improving the offing of therapy of chronic hepatitis B. These new therapeutic advances are reviewed in this manuscript.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716414     DOI: 10.1016/j.antiviral.2006.04.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  20 in total

1.  Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.

Authors:  Yu-Ping Wang; Fei Liu; Hong-Wei He; Yan-Xin Han; Zong-Gen Peng; Bao-Wei Li; Xue-Fu You; Dan-Qing Song; Zhuo-Rong Li; Li-Yan Yu; Shan Cen; Bin Hong; Chen-Heng Sun; Li-Xun Zhao; Barry Kreiswirth; David Perlin; Rong-Guang Shao; Jian-Dong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Hepatitis B virus replication.

Authors:  Juergen Beck; Michael Nassal
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 3.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

4.  Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.

Authors:  Rosendo Jardi; Francisco Rodriguez-Frias; David Tabernero; Maria Homs; Melanie Schaper; Rafael Esteban; Maria Buti
Journal:  J Clin Microbiol       Date:  2008-12-03       Impact factor: 5.948

5.  Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine.

Authors:  Fotinie Ntziora; Dimitrios Paraskevis; Catherine Haida; Emanuel Manesis; George Papatheodoridis; Spilios Manolakopoulos; Ioannis Elefsiniotis; Timokratis Karamitros; Alexis Vassilakis; Angelos Hatzakis
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

Review 6.  Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.

Authors:  Pan Zhao; Weiwei Liu; Jun Zhao; Qun Guan
Journal:  Virol J       Date:  2011-02-22       Impact factor: 4.099

7.  Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.

Authors:  Shirine Benhenda; Aurélie Ducroux; Lise Rivière; Bijan Sobhian; Michael D Ward; Sarah Dion; Olivier Hantz; Ulrike Protzer; Marie-Louise Michel; Monsef Benkirane; Oliver J Semmes; Marie-Annick Buendia; Christine Neuveut
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Four conserved cysteine residues of the hepatitis B virus polymerase are critical for RNA pregenome encapsidation.

Authors:  Seahee Kim; Jehan Lee; Wang-Shick Ryu
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

9.  Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion.

Authors:  Haifeng Wang; Wang-Shick Ryu
Journal:  PLoS Pathog       Date:  2010-07-15       Impact factor: 6.823

10.  Effects of two novel nucleoside analogues on different hepatitis B virus promoters.

Authors:  Xing-Xing He; Ju-Sheng Lin; Ying Chang; Ying-Hui Zhang; Yan Li; Xiao-Yan Wang; Dong Xu; Xiao-Ming Cheng
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.